4.40
-0.02 (-0.34%)
| Previous Close | 4.41 |
| Open | 4.50 |
| Volume | 131,906 |
| Avg. Volume (3M) | 1,953,150 |
| Market Cap | 868,178,240 |
| Price / Earnings (TTM) | 5.30 |
| Price / Sales | 4.44 |
| Price / Book | 3.34 |
| 52 Weeks Range | |
| Earnings Date | 5 Aug 2026 |
| Operating Margin (TTM) | -738.49% |
| Diluted EPS (TTM) | -0.410 |
| Quarterly Revenue Growth (YOY) | 15.10% |
| Total Debt/Equity (MRQ) | 7.07% |
| Current Ratio (MRQ) | 6.01 |
| Operating Cash Flow (TTM) | -58.95 M |
| Levered Free Cash Flow (TTM) | -28.88 M |
| Return on Assets (TTM) | -31.58% |
| Return on Equity (TTM) | -79.02% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Arbutus Biopharma Corporation | Mixed | Mixed |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -0.5 |
| Average | 1.33 |
|
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 21.89% |
| % Held by Institutions | 59.38% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Two Seas Capital Lp | 31 Mar 2026 | 18,557,543 |
| Blackbarn Capital Partners Lp | 31 Mar 2026 | 2,500,000 |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |